These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7933404)

  • 21. Multiple sclerosis: monotherapy rules.
    Hauser SL; Josephson SA; Johnston SC
    Ann Neurol; 2013 Mar; 73(3):A5-6. PubMed ID: 23596013
    [No Abstract]   [Full Text] [Related]  

  • 22. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment.
    Lucchinetti C; Brück W; Noseworthy J
    Curr Opin Neurol; 2001 Jun; 14(3):259-69. PubMed ID: 11371747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy in multiple sclerosis.
    Tullman MJ; Lublin FD
    Curr Neurol Neurosci Rep; 2005 May; 5(3):245-8. PubMed ID: 15865891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 29-year-old man with multiple sclerosis.
    Rudick RA
    JAMA; 1998 Oct; 280(16):1432-9. PubMed ID: 9801004
    [No Abstract]   [Full Text] [Related]  

  • 25. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
    Duddy M; Palace J
    Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247
    [No Abstract]   [Full Text] [Related]  

  • 26. Trial of interferon-beta in multiple sclerosis stopped early.
    Bonn D
    Lancet; 1998 Feb; 351(9102):573. PubMed ID: 9492786
    [No Abstract]   [Full Text] [Related]  

  • 27. Investigational drug therapies of treatment of multiple sclerosis.
    Panitch HS
    Mult Scler; 1996 Sep; 2(2):66-77. PubMed ID: 9345383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J; Cristiano E
    Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
    Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
    J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Workshop on primary progressive multiple sclerosis: meeting summary.
    Montalban X; Thompson AJ
    Mult Scler; 2002 Apr; 8(2):177-8. PubMed ID: 11990876
    [No Abstract]   [Full Text] [Related]  

  • 31. Confusion over UK beta-interferon "trials".
    Dean M
    Lancet; 2001 Nov; 358(9293):1619. PubMed ID: 11716901
    [No Abstract]   [Full Text] [Related]  

  • 32. Disease modifying therapies in multiple sclerosis: could a baseline thyroid check-up drive the therapeutic choice between interferon-β and glatiramer acetate?
    Rotondi M; Bergamaschi R; Chiovato L
    Mult Scler; 2014 Dec; 20(14):1918-9. PubMed ID: 24812044
    [No Abstract]   [Full Text] [Related]  

  • 33. The use of interferon Beta and glatiramer acetate in multiple sclerosis.
    Goodin DS
    Semin Neurol; 2013 Feb; 33(1):13-25. PubMed ID: 23709209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Unresolved problems and the prospects for research in area of the multiple sclerosis: virologic, immunologic and therapeutic aspects].
    Mal'tsev DV
    Lik Sprava; 2014; (5-6):3-19. PubMed ID: 25906643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon beta-1A for multiple sclerosis.
    Drug Ther Bull; 1998 Jan; 36(1):7-8. PubMed ID: 9614724
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
    Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
    Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Disease-modifying treatments in multiple sclerosis].
    Confavreux C; Bouhour F; Vukusic S
    Rev Prat; 1999 Nov; 49(17):1882-9. PubMed ID: 10598505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The multiple sclerosis market.
    Huynh T
    Nat Rev Drug Discov; 2010 Oct; 9(10):759-60. PubMed ID: 20885402
    [No Abstract]   [Full Text] [Related]  

  • 40. New treatments for multiple sclerosis.
    Hutchinson M
    Ir Med J; 1996; 89(2):44. PubMed ID: 8682623
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.